[Latin Name] Amorphophallus konjac

[Plant Source] from China

[Specifications] Glucomannan85%-90%

[Appearance] White or cream-color powder

Plant Part Used:Root

[Particle size] 120 Mesh

[Loss on drying] ≤10.0%

[Heavy Metal] ≤10PPM

[Storage] Store in cool & dry area, keep away from the direct light and heat.

[Shelf life] 24 Months

[Package] Packed in paper-drums and two plastic-bags inside.

[Net weight] 25kgs/drum

[Introduction]

Konjac is a plant that is found in China, Japan and Indonesia. The plant is part of the genus Amorphophallus. Typically, it thrives in the warmer regions of Asia.

The extract of the Konjac root is referred to as Glucomannan. Glucomannan is a fiber-like substance traditionally used in food recipes, but now it is utilized as an alternative means of weight loss. Along with this benefit, konjac extract contains other benefits for the rest of the body as well.

The main material of the natural konjac gum is fresh konjac, which grow in virgin forest in Hubei area. We use advanced method to distill the KGM, aminophenol, Ca, Fe, Se which are good for health. Konjac is known as“ the seventh nutriment for human”.

Konjac Gum with its special water holiding capacity, stability, emulsibility, thickening property,suspension property and gel propery can especially adopted in food industry.

[Main Function]

1.It could reduce postprandial glycemia, blood cholesterol and blood pressure.

2.It could control appetite and reduce body weight.

3.It could increase insulin sensitivity.
4.It could control insulin resistant syndrome and diabetesII development.
5.It could reduce heart disease.

[Application]

1) Gelatinizer(jelly, pudding, Cheese, soft candy, jam );

2) Stabilizer(meat, beer);

3) Film Former(capsule, preservative)

4) Water-keeping agent( Baked Foodstuff );

5) Thickener (Konjac Noodles, Konjac Stick, Konjac Slice, Konjac Imitating Food stuff);

6) Adherence agent( Surimi );

7) Foam Stabilizer (ice cream, cream, beer)

Jose S. Pulido, M.D., Professor of Opthalmology & Molecular Medicine, Mayo Clinic College of Medicine and Alan D. Marmorstein, Ph.D., Professor of Ophthalmology, Mayo Clinic College of Medicine discuss the importance of genetic testing in diagnosing macular degeneration. Three cases are outlined that have been referred to as Adult Onset Foveomacular Dystrophy, Macular Degeneration, and Best Disease. Genetic testing can be used to make these diagnoses and researchers are at the threshold of new and exciting treatments. Over the past few years Dr. Marmorstein’s laboratory has been involved in a study of stem cell models of Best Disease and other retinal degenerative diseases. Details can be found on the NIH web site. DNA is being collected along with skin fibroblasts from patients with Best Disease Adult Vitelliform Dystrophy Autosomal Recessive Bestrophinopathy, autosomal dominant vitreoretinal choroidopathy, and retinitis pigmentosa due to mutations in BEST1. The skin fibroblasts are being reprogrammed into induced pluripotent stem cells which can be differentiated into retinal pigment epithelial cells. This is the cell where Bestrophin, the product of the BEST1 gene is expressed and that’s where the pathogenic problem that results in these diseases occurs. Clinical trials are already underway using iPS cell derived retinal pigment epithelial cells for the treatment of age-related Macular Degeneration. It also allows the consideration of the same process to therapeutically treat Best Disease and Adult Vitelliform Macular Dystrophy, Autosomal Recessive Bestrophinopathy and models of the diseases can be generated of the diseases in the laboratory. This can help with the understanding of the processes that cause the disease and allow for the testing of potential therapeutic compounds to determine if they have an effect on these specific patients.

For more information, visit: https://www.mayoclinic.org/departments-centers/ophthalmology?mc_id=us&utm_source=youtube&utm_medium=sm&utm_content=video&utm_campaign=mayoclinic&geo=national&placementsite=enterprise&cauid=100504